■脆性X综合征(FXS)是智力障碍和自闭症谱系障碍的主要单基因原因。目前,没有确定的生物标志物来预测和监测FXS中的药物作用,没有批准的疗法。以前的研究表明,在FXS和动物模型的个体中,使用脑电图(EEG)可以改变大脑的电生理变化。这些变化可能受到药物治疗的影响。在这项研究中,我们旨在评估FXS患者静息状态脑电图测量的可靠性,这可能是药物发现的生物标志物。
■我们收集了参与安慰剂对照临床试验的35名FXS患者的静息状态脑电图数据(23名男性,12名女性;就诊年龄平均+/-std25.6+/-8.3)。使用组内相关性分析对数据进行各种光谱特征的分析,以评估重测可靠性。EEG记录之间的间隔范围从当天的测量到间隔长达六周。
■我们的结果显示了大多数光谱特征的高可靠性,当天的可靠性超过0.8。感兴趣的特征在更长的时间间隔证明了0.60或更高的ICC值。在这些特征中,α波段相对功率表现出最高的可靠性。
■这些发现表明,静息状态EEG可以为FXS患者的大脑活动提供一致且可重复的测量。这支持EEG作为客观生物标志物用于评估新药物在FXS中的作用的潜在用途。
■从基于功率谱的静息状态EEG获得的可靠测量使其成为评估小分子药物在FXS中影响的有希望的工具。
UNASSIGNED: Fragile X Syndrome (FXS) is the leading monogenic cause of intellectual disability and autism spectrum disorder. Currently, there are no established biomarkers for predicting and monitoring drug effects in FXS, and no approved therapies are available. Previous studies have shown electrophysiological changes in the brain using electroencephalography (EEG) in individuals with FXS and animal models. These changes may be influenced by drug therapies. In this study, we aimed to assess the reliability of resting-state EEG measures in individuals with FXS, which could potentially serve as a biomarker for drug discovery.
UNASSIGNED: We collected resting-state EEG data from 35 individuals with FXS participating in placebo-controlled clinical trials (23 males, 12 females; visit age mean+/-std 25.6 +/-8.3). The data were analyzed for various spectral features using intraclass correlation analysis to evaluate test-retest reliability. The intervals between EEG recordings ranged from same-day measurements to up to six weeks apart.
UNASSIGNED: Our results showed high reliability for most spectral features, with same-day reliability exceeding 0.8. Features of interest demonstrated ICC values of 0.60 or above at longer intervals. Among the features, alpha band relative power exhibited the highest reliability.
UNASSIGNED: These findings indicate that resting-state EEG can provide consistent and reproducible measures of brain activity in individuals with FXS. This supports the potential use of EEG as an objective biomarker for evaluating the effects of new drugs in FXS.
UNASSIGNED: The reliable measurements obtained from power spectrum-based resting-state EEG make it a promising tool for assessing the impact of small molecule drugs in FXS.